Jija Issac
Family · Carmichael, CANPI 1235919812
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,192 of the $8,087 with a category attached, or 88.9%. It is spread thinly across 42 manufacturers, the largest accounting for just 10.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $4,136, 6.9 times the $600 reported in 2023. Among family clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 321 payments — averaging $25.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$841
- Johnson & Johnson$778
- Pfizer$757
- Astellas Pharma US Inc$580
- Merck$469
- Incyte Corporation$440
- plus $4K from 36 others
What the payments were for
- Food & beverage$7,19289%
- Education$89511%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,087 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 11 | $130,126 |
| EliquisApixaban | 18 | $12,852 |
| Exemestane | 19 | $2,180 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 69 | $1,890 |
| Ondansetron Hcl | 30 | $721 |
| Dexamethasone | 33 | $623 |
| Potassium Chloride | 64 | $616 |
| LoperamideLoperamide Hcl | 48 | $613 |
| Oxycodone Hcl | 17 | $578 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 18 | $444 |
| Anastrozole | 25 | $420 |
| Acyclovir | 17 | $398 |
| Ondansetron OdtOndansetron | 16 | $358 |
| Morphine Sulfate ErMorphine Sulfate | 13 | $270 |
| Gabapentin | 25 | $260 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence | $841 | $130,12611 claims |
| PfizerEliquis | $757 | $12,85218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.
Other family in Carmichael
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
- Erin DwyerSan Diego$189K
- Phyllis CasonLos Angeles$187K
- Gabriel SchwartzSan Francisco$166K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.